Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
第一作者:
George I,Papakostas
第一单位:
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA. gpapakostas@partners.org
作者:
主题词
成年人(Adult);抗精神病药(Antipsychotic Agents);抑郁症, 更年期(Depressive Disorder, Major);剂量效应关系, 药物(Dose-Response Relationship, Drug);用药计划表(Drug Administration Schedule);抗药性(Drug Resistance);药物疗法, 联合(Drug Therapy, Combination);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);人格评价(Personality Assessment);个性量表(Personality Inventory);哌嗪类(Piperazines);心理测定学(Psychometrics);血清素5-HT1受体激动剂(Serotonin 5-HT1 Receptor Agonists);噻唑类(Thiazoles);治疗结果(Treatment Outcome)
DOI
10.4088/jcp.v65n0212
PMID
15003076
发布时间
2022-12-07
- 浏览34
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文